CClinicalTrials.gg
Not yet recruitingNCT07452094Updated Mar 5, 2026

What is the Role of Type III/IV Muscle Afferents in Airway Resistance and Thermoregulatory Responses to Exercise?

An Early Phase 1 interventional study of EXERCISE TRAINING WITH OR WITHOUT MEDICATION in Placebo - Control and Experimental, sponsored by Northern Arizona University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Northern Arizona University · Early Phase 1, Interventional, and Basic science

Phase
Early Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Exercise places serious demands on the body. These demands are fundamentally caused by increases in oxygen demand and the consequent increase in body temperature. These demands are met by several physiological responses, including increases in heart rate, blood pressure, breathing and blood flow. These responses must be proportional to the increase in demand and some signal must relay information from the muscle to the brain. Group III/IV afferents do just this. They relay information about the muscle (movement, temperature, acidity, etc.) up to the brain so that appropriate responses are mounted. There is strong evidence in animals that group III/IV afferents play a key role in making breathing easier (decreasing airway resistance) and initiating sweating and blood flow responses. There has been no research on the role of group III/IV afferents on these fundamental exercise responses in humans. The investigators propose to isolate the role of group III/IV afferents on regulate airway resistance, sweating and blood flow responses to exercise in humans.

Read the detailed description

Group III/IV afferents are nerves that relay information from the muscles to the central nervous system. This afferent activity acts as negative feedback to minimize the overall strain placed on muscles . Without this negative feedback, locomotor muscles become damaged during intense exercise. It is well-established that group III/IV afferents are required for normal breathing and blood pressure responses to physical activity. In certain disease states, such as chronic obstructive pulmonary disease, heart failure and hypertension, group III/IV afferents become dysfunctional and lead to exercise intolerance. This is a major issue in these patient groups where regular exercise is advocated to slow or halt disease progression. Understanding how these reflexes contribute to basic cardiorespiratory responses to exercise is thus warranted.

At the onset of exercise, there is a near instantaneous decrease in airway resistance that permits high rates of breathing ; these high rates of breathing are essential to ensure appropriate oxygen transport to working muscles. The decrease in airway resistance is facilitated by a rapid withdrawal of parasympathetic tone to the smooth muscle lining the airways, allowing them to open up and remain rigid. Evidence in cats and dogs indicate that group III/IV afferents reflexively contribute to this response, thereby coupling airway dilation to muscle work. Airway resistance can be quantified by measuring the work required by breathing muscles to pull air into and push air out of the lungs. If the magnitude of airway dilation changes due to the suppression of group III/IV afferents, the investigators would observe a compensatory increase in how much work is required to overcome resistance. This has not been investigated directly in humans.

Alongside the fundamental cardiorespiratory responses to exercise, humans mount powerful thermoregulatory responses that dissipate heat generated from muscle work. The primary thermoregulatory responses in humans are eccrine sweating and skin vasodilation; both of which are activated as body temperature rises. Exercise augments thermoregulatory responses to heating, and sweating is initiated within 1-2 seconds of initiating exercise despite body temperature remaining stable. Thus, there is clearly a link between muscular work and thermoregulation. Reduced preparations in cats have shown that group III/IV afferent activity is elevated during external muscle heating, and human sweating responses are more closely coupled to muscle temperature than to core or skin temperature. To date, no study in humans has tried to isolate the role of group III/IV afferents on thermoregulatory responses to exercise.

These group III/IV afferents can be studied in exercising humans by suppressing their activity using intrathecal (spinal) opioids. Simply, a subject exercises on two different occasions, one with intact muscle reflex feedback, and the other with the feedback suppressed; differences in exercise responses are isolated to the role of group III/IV afferents. The investigators aim to use this model to quantify the contribution of group III/IV afferent reflexes to airway resistance, sweating and skin vasodilation.

02

Conditions studied

  • Placebo - Control
  • Experimental

Browse trials for

Keywords

  • Group III/IV afferents
  • exercise
  • thermoregulation
  • sweating
  • blood flow
  • airway resistance
03

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • regularly physically active as determined via questionnaires (Par-Q \& You)
  • maximal aerobic power 30 mL/min/kg (female), 40 mL/kg/min (male)

Exclusion criteria

Exclusion Criteria:

  • current smokers
  • acute bronchial asthma
  • diabetics
  • chronic back pain
  • peripheral neuropathy
  • chronic obstructive airway or status asthmaticus
  • obese (body mass index > 30 kg/m2)
  • convulsive disorders
  • requiring daily medications that may affect responses to exercise (e.g. anti-hypertensive, anti-arrhythmogenics, blood thinners)
  • history of drug abuse
  • history of disease/dysfunction that could cause complication with exercise (e.g. cardiovascular, respiratory, neurological, musculoskeletal)
  • irregular or absent menstrual cycle
  • pregnant or suspected pregnancy
  • adverse response to physical exercise
  • current or history of esophageal or gastric disease, or frequent heart burn (>2x per week)
  • Lidocaine allergy
04

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
15 participants (estimated)

Study arms

  • Placebo comparator
    Placebo-control

    Exercise with saline injection

    Drug: EXERCISE TRAINING WITH OR WITHOUT MEDICATION

  • Experimental
    Group III/IV afferent blockade

    Feedback from group III/IV afferents is blocked

    Drug: EXERCISE TRAINING WITH OR WITHOUT MEDICATION

Interventions

  • DrugEXERCISE TRAINING WITH OR WITHOUT MEDICATION

    Cycling exercise with group III/IV afferent feedback blocked via drug

05

What researchers measure

Primary outcomes

  1. Airway resistance

    Calculated based of work of breathing and ventilation flow rate

    Time frame: 2 weeks

  2. Sweat rate

    Local eccrine sweat rates at 3 different sites

    Time frame: 2 weeks

  3. Skin blood flow

    Skin blood flux measured at different skin sites

    Time frame: 2 weeks

06

Study locations

1 site
  • Northern Arizona University
    Flagstaff, Arizona 86011, United States
    • TRAVIS D GIBBONS, PhD · Contact · travis.gibbons@nau.edu · 9282558769
    • RILEY CONNOR, MS · Sub investigator
    • TRAVIS D GIBBONS, PhD · Principal investigator
07

References and documents

Individual participant data

Plan to share: No — I am concerned for privacy protection of our participants.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07452094
Lead sponsor
Northern Arizona University
Responsible party
Sponsor
First posted
Mar 5, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Mar 5, 2026

Study contacts

TRAVIS D GIBBONS, PhD
Contact
travis.gibbons@nau.edu
19282558769
TRAVIS D GIBBONS, PhD
principal investigator · Northern Arizona University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion